NewAmsterdam Pharma Warrant
NAMSW
10 hedge funds and large institutions have $12.3M invested in NewAmsterdam Pharma Warrant in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.22% less ownership
Funds ownership: 1.43% → 1.21% (-0.22%)
9% less funds holding
Funds holding: 11 → 10 (-1)
34% less capital invested
Capital invested by funds: $18.8M → $12.3M (-$6.43M)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$43.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$191K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$41.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.09K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FLSM
1
Frazier Life Sciences Management
Palo Alto,
California
| $4.5M | – | – | – |
|
|
RCM
2
RA Capital Management
Boston,
Massachusetts
| $3M | – | – | – |
|
|
AAA
3
Affinity Asset Advisors
New York
| $2.75M | +$43.9K | +4,022 | +2% |
|
|
BCLSI
4
Bain Capital Life Sciences Investors
Boston,
Massachusetts
| $899K | – | – | – |
|
|
DM
5
Deerfield Management
New York
| $834K | – | – | – |
|
|
LCM
6
Laurion Capital Management
New York
| $150K | – | – | – |
|
|
VI
7
Vestcor Inc
Fredericton,
New Brunswick, Canada
| $91K | – | – | – |
|
|
WAM
8
Wolverine Asset Management
Chicago,
Illinois
| $79.9K | -$41.6K | -3,809 | -30% |
|
|
9
UBS Group
Zurich,
Switzerland
| $21.4K | -$1.09K | -100 | -4% |
|
10
CIBC Private Wealth Group
Atlanta,
Georgia
| $6.15K | – | – | – |
|
|
HF
11
HRT Financial
New York
| – | -$191K | -13,655 | Closed |
|
NAMSW Hedge Fund Activity: Q1 2025 in Review
10 of the 7,460 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma Warrant (NAMSW) for Q1 2025, worth a combined $12.3M — down 34% from $18.8M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NAMSW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Affinity Asset Advisors, adding an estimated $43.9K. The largest seller was HRT Financial, exiting entirely with an estimated $191K sold.
- 10 institutional investors held NewAmsterdam Pharma Warrant (NAMSW) as of Q1 2025, down from 11 in Q4 2024.
- Funds reported $12.3M of NewAmsterdam Pharma Warrant stock for Q1 2025, down 34% quarter-over-quarter.
- 0 funds opened new NewAmsterdam Pharma Warrant positions in Q1 2025 and 1 closed out, a net change of -1 holder.
- The largest NewAmsterdam Pharma Warrant buyer in Q1 2025 was Affinity Asset Advisors, an estimated $43.9K added.
- The largest NewAmsterdam Pharma Warrant seller in Q1 2025 was HRT Financial, an estimated $191K sold.
Based on aggregated 13F filings for Q1 2025.